1. Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD. Issue 9 (8th April 2021) Authors: Srinivasan, Ashish; Haifer, Craig; Thin, Lena Journal: Alimentary pharmacology & therapeutics Issue: Volume 53:Issue 9(2021) Page Start: 1038 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. Issue 7 (July 2018) Authors: Chan, Webber; Lynch, Nicole; Bampton, Peter; Chang, Jeff; Chung, Alvin; Florin, Timothy; Hetzel, David J.; Jakobovits, Simon; Moore, Gregory; Pavli, Paul; Radford-Smith, Graham; Thin, Lena; Baraty, Brandon; Haifer, Craig; Yau, Yunki; Leong, Rupert W.L. Journal: European journal of gastroenterology & hepatology Issue: Volume 30:Issue 7(2018:Jul.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Abdulkhakov, Rustem; Abu ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab. Issue 9 (7th October 2021) Authors: Srinivasan, Ashish; Haifer, Craig; Thin, Lena Journal: Medical journal of Australia Issue: Volume 215:Issue 9(2021) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Issue 3 (17th October 2020) Authors: Haifer, Craig; Srinivasan, Ashish; An, Yoon‐Kyo; Picardo, Sherman; van Langenberg, Daniel; Menon, Shankar; Begun, Jakob; Ghaly, Simon; Thin, Lena Journal: Medical journal of Australia Issue: Volume 214:Issue 3(2021) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The Effect of Adiposity on Anti–Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients. Issue 9 (22nd September 2020) Authors: Lim, Zixiang; Welman, Christopher J.; Raymond, Warren; Thin, Lena Journal: Clinical and translational gastroenterology Issue: Volume 11:Issue 9(2020) Page Start: e00233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗